234 related articles for article (PubMed ID: 16443251)
1. Estimated cancer risk of dioxins to humans using a bioassay and physiologically based pharmacokinetic model.
Maruyama W; Aoki Y
Toxicol Appl Pharmacol; 2006 Jul; 214(2):188-98. PubMed ID: 16443251
[TBL] [Abstract][Full Text] [Related]
2. Modeling and assaying dioxin-like biological effects for both dioxin-like and certain non-dioxin-like compounds.
Wilkes JG; Hass BS; Buzatu DA; Pence LM; Archer JC; Beger RD; Schnackenberg LK; Halbert MK; Jennings L; Kodell RL
Toxicol Sci; 2008 Mar; 102(1):187-95. PubMed ID: 18065775
[TBL] [Abstract][Full Text] [Related]
3. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
[TBL] [Abstract][Full Text] [Related]
4. A sensitivity analysis using alternative toxic equivalency factors to estimate U.S. dietary exposures to dioxin-like compounds.
Parvez S; Evans AM; Lorber M; Hawkins BS; Swartout JC; Teuschler LK; Rice GE
Regul Toxicol Pharmacol; 2013 Nov; 67(2):278-84. PubMed ID: 23973911
[TBL] [Abstract][Full Text] [Related]
5. A mixture of dioxins, furans, and non-ortho PCBs based upon consensus toxic equivalency factors produces dioxin-like reproductive effects.
Hamm JT; Chen CY; Birnbaum LS
Toxicol Sci; 2003 Jul; 74(1):182-91. PubMed ID: 12730615
[TBL] [Abstract][Full Text] [Related]
6. Comparison of intake and systemic relative effect potencies of dioxin-like compounds in female rats after a single oral dose.
van Ede KI; Andersson PL; Gaisch KP; van den Berg M; van Duursen MB
Arch Toxicol; 2014 Mar; 88(3):637-46. PubMed ID: 24363026
[TBL] [Abstract][Full Text] [Related]
7. Possible range of dioxin concentration in human tissues: simulation with a physiologically based model.
Maruyama W; Yoshida K; Tanaka T; Nakanishi J
J Toxicol Environ Health A; 2002 Dec; 65(24):2053-73. PubMed ID: 12515586
[TBL] [Abstract][Full Text] [Related]
8. Carcinogenic risks of dioxin: mechanistic considerations.
Schwarz M; Appel KE
Regul Toxicol Pharmacol; 2005 Oct; 43(1):19-34. PubMed ID: 16054739
[TBL] [Abstract][Full Text] [Related]
9. Dose-response relationships for disposition and hepatic sequestration of polyhalogenated dibenzo-p-dioxins, dibenzofurans, and biphenyls following subchronic treatment in mice.
DeVito MJ; Ross DG; Dupuy AE; Ferrario J; McDaniel D; Birnbaum LS
Toxicol Sci; 1998 Dec; 46(2):223-34. PubMed ID: 10048125
[TBL] [Abstract][Full Text] [Related]
10. A physiologically based pharmacokinetic model for 2,3,7,8-tetrabromodibenzo-p-dioxin (TBDD) in the rat: tissue distribution and CYP1A induction.
Kedderis LB; Mills JJ; Andersen ME; Birnbaum LS
Toxicol Appl Pharmacol; 1993 Jul; 121(1):87-98. PubMed ID: 8337704
[TBL] [Abstract][Full Text] [Related]
11. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
12. Effects of polychlorinated dibenzofurans, biphenyls, and their mixture with dibenzo-p-dioxins on ovulation in the gonadotropin-primed immature rat: support for the toxic equivalency concept.
Gao X; Terranova PF; Rozman KK
Toxicol Appl Pharmacol; 2000 Mar; 163(2):115-24. PubMed ID: 10698669
[TBL] [Abstract][Full Text] [Related]
13. Tissue distribution of dioxin-like compounds: potential impacts on systemic relative potency estimates.
van Ede KI; Aylward LL; Andersson PL; van den Berg M; van Duursen MB
Toxicol Lett; 2013 Jul; 220(3):294-302. PubMed ID: 23680695
[TBL] [Abstract][Full Text] [Related]
14. Applicability of the CALUX bioassay for screening of dioxin levels in human milk samples.
Laier P; Cederberg T; Larsen JC; Vinggaard AM
Food Addit Contam; 2003 Jun; 20(6):583-95. PubMed ID: 12881133
[TBL] [Abstract][Full Text] [Related]
15. [Impacts and impact mechanisms of "dioxins" in humans and animals].
Nau H
Dtsch Tierarztl Wochenschr; 2006 Aug; 113(8):292-7. PubMed ID: 16955640
[TBL] [Abstract][Full Text] [Related]
16. Comparison of intake and systemic relative effect potencies of dioxin-like compounds in female mice after a single oral dose.
van Ede KI; Andersson PL; Gaisch KP; van den Berg M; van Duursen MB
Environ Health Perspect; 2013 Jul; 121(7):847-53. PubMed ID: 23674508
[TBL] [Abstract][Full Text] [Related]
17. Relative differences in aryl hydrocarbon receptor-mediated response for 18 polybrominated and mixed halogenated dibenzo-p-dioxins and -furans in cell lines from four different species.
Olsman H; Engwall M; Kammann U; Klempt M; Otte J; Bavel Bv; Hollert H
Environ Toxicol Chem; 2007 Nov; 26(11):2448-54. PubMed ID: 17941736
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of relative effect potencies (REPs) for dioxin-like compounds to derive systemic or human-specific TEFs to improve human risk assessment.
van Ede KI; van Duursen MB; van den Berg M
Arch Toxicol; 2016 Jun; 90(6):1293-305. PubMed ID: 27161441
[TBL] [Abstract][Full Text] [Related]
19. Determination of relative assay response factors for toxic chlorinated and brominated dioxins/furans using an enzyme immunoassay (EIA) and a chemically-activated luciferase gene expression cell bioassay (CALUX).
Samara F; Gullett BK; Harrison RO; Chu A; Clark GC
Environ Int; 2009 Apr; 35(3):588-93. PubMed ID: 19121869
[TBL] [Abstract][Full Text] [Related]
20. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
